Quixolabs provides predictive studies of blood–brain barrier penetration and potential CNS Drug-Drug Interactions by using unique models.
Blood–brain barrier penetration of small molecules:
- Brain–barrier permeability – the brain uptake rate
- Extent of brain uptake
- Estimation of the free fraction in the brain
Potential Drug-Drug Interactions and metabolism (CNS):
- Interactions with CYP3A4 and P-glycoprotein
- Interactions with specific reference CYP substrates and inhibitors
- Saturations studies of CYPs and transporters, evaluate unknown interactions
- Metabolism (quantification of known metabolites and/or metabolite ID)
The combination of the brain–barrier permeability and the free fraction in the brain in early drug discovery is useful for rank-ordering CNS compounds and is more appropriate to correlate with free drug concentrations than either property alone. Measuring the free fraction becomes important when the lipophilicity of the compounds increases, and permeability is an important factor for compounds characterized by low brain tissue binding, i.e., high free fraction.